一个幻觉激活的Gq-合的5-HT2A血清素受体的结构
Kuglae Kim1, Tao Che1, Ouliana Panova2
1Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA.
Cell
|September 18, 2020
概括
揭示了像LSD和psilocybin这样的幻觉剂如何激活5-HT2A受体 (HTR2A) 的结构性见解. 了解这些分子机制是开发神经精神疾病新疗法的关键.
科学领域:
- 神经科学
- 药理学
- 结构生物学
背景情况:
- 迷幻药,包括lysergic acid diethylamide (LSD) 和psilocybin,以其娱乐用途和神经精神疾病的新兴治疗潜力而闻名.
- 5-HT2A 血清素受体 (HTR2A) 是迷幻药的治疗和幻觉效应的关键目标.
- 精确的分子机制背后的迷幻作用在HTR2A仍然不完全理解.
研究的目的:
- 在HTR2A中阐明迷幻药物作用的分子基础.
- 确定HTR2A与幻觉剂和G蛋白质复合的活性结构.
- 将HTR2A与不同连接体结合的结构进行比较,以了解激活和信号.
主要方法:
- 使用冷电子显微镜 (cryo-EM) 来确定与25-CN-NBOH结合的HTR2A和一个Gαq异构体的结构.
- 使用X射线结晶学检测了HTR2A与LSD (一种阿雷斯偏差联结体) 和美西 (一种反向激动剂) 复合的结构.
主要成果:
- 确定了HTR2A与幻觉剂25-CN-NBOH结合于Gαq的活性状态结构.
- 结构比较揭示了HTR2A激活所涉及的关键相互作用和形状变化.
- 结构上的差异突出了G蛋白与阿斯特林合的决定因素.
结论:
- 这些结构发现提供了分子洞察力,
- 了解这些相互作用可以指导神经精神疾病的新选择性治疗方法的设计.
- 这项研究加速了针对HTR2A的药物的发现,
相关概念视频
G-protein Coupled Receptors
130.0K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
130.0K
CNS Stimulants: Psychedelic Agents
497
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
497
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
740
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
740
G-Protein Gated Ion Channels
5.4K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
5.4K
G Protein-coupled Receptors
15.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
15.5K
Transducer Mechanism: G Protein–Coupled Receptors
3.5K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
3.5K


